<DOC>
	<DOCNO>NCT02222363</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability investigational drug VLX600 patient refractory advance solid tumor .</brief_summary>
	<brief_title>Study Safety Tolerability VLX600 , Iron Chelator , Patients With Refractory Advanced Solid Tumors</brief_title>
	<detailed_description>This Phase I , open label dose escalation study VLX600 patient refractory advance solid tumor determine safety profile maximum tolerate dose ( MTD ) VLX600 administer intravenous infusion Days 1 , 8 , 15 28-day treatment cycle . Dose escalation proceed accord standard `` 3 + 3 '' design use double dos . The dos : 10 , 20 , 40 , 80 , 160 , 210 mg VLX600 .</detailed_description>
	<mesh_term>Chelating Agents</mesh_term>
	<criteria>1 . Men woman great equal 18 year age . 2 . Histologic evidence advance solid tumor ( exclude central nervous system ( CNS ) primary tumor ) nonresectable , refractory standard therapy , patient receive refuse standard therapy . 3 . Solid tumor measurable accord RECIST 1.1 solid tumor measurable accord RECIST 1.1 , express tumor marker ( e.g. , prostate cancer prostate specific antigen ( PSA ) expression ovarian cancer cancer antigen125 ( CA125 ) expression ) eligible . 4 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 . 5 . Must follow laboratory value , obtain less equal 7 day prior registration : Absolute neutrophil count ( ANC ) great equal 1500/µL Platelet ( PLT ) count great equal 100,000/µL Total bilirubin le 1.5 x upper normal limit ( UNL ) Aspartate aminotransferase ( AST ) ( SGOT ) less equal 3 x UNL Creatinine le 1.5 x UNL 6 . Women childbearing potential must negative serum pregnancy test less equal 7 day prior registration . 7 . Life expectancy great 12 week . 8 . Must provide write informed consent . 9 . Must willing return Mayo Clinic enrol institution followup . 1 . Uncontrolled intercurrent illness include , limited , ongoing active infection , diabetes mellitus , seizure disorder psychiatric illness/social situation would limit compliance study requirement . 2 . Treatment follow prior therapy : Chemotherapy le equal 4 week prior registration Mitomycin C/nitrosoureas less equal 6 week prior registration Immunotherapy le equal 4 week prior registration Biologic therapy less equal 4 week prior registration Radiation therapy less equal 4 week prior registration Noncytotoxic therapy less equal 5 halflives prior registration 3 . Failure fully recover acute , reversible effect prior chemotherapy regardless interval since last treatment . 4 . Major surgery le 28 day prior study entry . 5 . Active malignancy , except nonmelanoma skin cancer carcinomainsitu ( e.g. , cervix , breast , prostate ) . If history prior malignancy , patient must receive specific treatment ( hormonal therapy ) cancer . 6 . CNS metastases previously treat stable least 2 month per image clinical assessment . 7 . Any following study involve investigational agent whose genotoxic , mutagenic teratogenic effect develop fetus newborn unknown : Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception 8 . Other concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational ( utilized nonFDAapproved indication context research investigation ) receive investigational agent would consider treatment primary neoplasm . 9 . Cardiac issue consist either symptomatic congestive heart failure ( NYHA Class II high ) , unstable angina pectoris , myocardial infarction within 6 month , and/or cardiac arrhythmia , include atrial fibrillation ( symptomatic require treatment ) . 10 . Corrected QT interval ( QTc ) interval great 450 msec ( male ) great 470 msec ( female ) . 11 . Immunocompromised patient ( relate use corticosteroid ) include patient know history human immunodeficiency virus ( HIV ) active infection hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) . 12 . Clinically relevant retinal abnormality per medical history ophthalmologic finding pretreatment evaluation ( e.g. , retinitis pigmentosa macular degeneration ) . 13 . History thromboembolism within past 5 year , history catheterrelated thrombophlebitis clinically significant thrombophlebitis exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Iron chelator</keyword>
	<keyword>Refractory advance solid tumor</keyword>
	<keyword>Dose escalation study</keyword>
	<keyword>Safety tolerability</keyword>
	<keyword>Tumor response RECIST 1.1</keyword>
	<keyword>Progression-free survival</keyword>
	<keyword>Overall survival Pharmacokinetics</keyword>
</DOC>